Literature DB >> 19229109

PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.

Debora Franceschini1, Marino Paroli, Vittorio Francavilla, Melissa Videtta, Stefania Morrone, Giancarlo Labbadia, Antonella Cerino, Mario U Mondelli, Vincenzo Barnaba.   

Abstract

CD4+CD25+Foxp3+ Tregs suppress autoimmune responses. In addition, they limit T cell responses during chronic infection, thereby minimizing T cell-dependent immunopathology. We sought to investigate how Tregs are regulated in the livers of patients chronically infected with HCV, where they control the balance between an adequate protective immune response and suppression of immunopathology. We found that, despite accumulating and proliferating at sites of infection in the livers of patients chronically infected with HCV, Tregs were relatively less expanded than CD4+CD25+Foxp3- effector T cells. The relative lower expansion of intrahepatic Tregs coincided with their upregulation of programmed death-1 (PD-1). PD-1 expression inversely correlated with both Treg proliferation and clinical markers of immune suppression in vivo. Consistent with the possibility that PD-1 controls Tregs, blockade of the interaction between PD-1 and programmed death-1 ligand 1 (PD-L1) enhanced the in vitro expansion and function of Tregs isolated from the livers of patients chronically infected with HCV. Blockade of the interaction between PD-L1 and B7.1 also improved the proliferation of these cells. Interestingly, both PD-1 and phosphorylated STAT-5 were overexpressed in intrahepatic Tregs in a parallel fashion in steady disease conditions, and in an alternate-fluctuating fashion during the course of severe hepatitis reactivation. Notably, PD-L1 blockade upregulated STAT-5 phosphorylation in Tregs ex vivo. These data suggest that PD-L1 negatively regulates Tregs at sites of chronic inflammation by controlling STAT-5 phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229109      PMCID: PMC2648671          DOI: 10.1172/JCI36604

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  79 in total

1.  Friendly and dangerous signals: is the tissue in control?

Authors:  Polly Matzinger
Journal:  Nat Immunol       Date:  2007-01       Impact factor: 25.606

2.  Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.

Authors:  Luke M Williams; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2007-01-14       Impact factor: 25.606

3.  PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver.

Authors:  Holly Maier; Masanori Isogawa; Gordon J Freeman; Francis V Chisari
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

4.  Foxp3-dependent programme of regulatory T-cell differentiation.

Authors:  Marc A Gavin; Jeffrey P Rasmussen; Jason D Fontenot; Valeria Vasta; Vincent C Manganiello; Joseph A Beavo; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-14       Impact factor: 49.962

5.  Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  Nature       Date:  2007-01-14       Impact factor: 49.962

6.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.

Authors:  Lydie Trautmann; Loury Janbazian; Nicolas Chomont; Elias A Said; Sylvain Gimmig; Benoit Bessette; Mohamed-Rachid Boulassel; Eric Delwart; Homero Sepulveda; Robert S Balderas; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2006-08-20       Impact factor: 53.440

Review 7.  Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions.

Authors:  Joana Loureiro; Hidde L Ploegh
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

8.  Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Authors:  Henry Radziewicz; Chris C Ibegbu; Marina L Fernandez; Kimberly A Workowski; Kamil Obideen; Mohammad Wehbi; Holly L Hanson; James P Steinberg; David Masopust; E John Wherry; John D Altman; Barry T Rouse; Gordon J Freeman; Rafi Ahmed; Arash Grakoui
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

9.  PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.

Authors:  Simona Urbani; Barbara Amadei; Daniela Tola; Marco Massari; Simona Schivazappa; Gabriele Missale; Carlo Ferrari
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

Review 10.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

View more
  140 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

2.  Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection.

Authors:  Jie Liu; Tracy J Ruckwardt; Man Chen; John D Nicewonger; Teresa R Johnson; Barney S Graham
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 3.  PD-1, gender, and autoimmunity.

Authors:  Ravi K Dinesh; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-28       Impact factor: 9.754

4.  Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Mandana Zandian; Homayon Ghiasi
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

5.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

Review 6.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

7.  Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.

Authors:  Halvor S McGee; Hideo Yagita; Zhifei Shao; Devendra K Agrawal
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

8.  Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.

Authors:  Stephen R Goding; Kyle A Wilson; Ying Xie; Kristina M Harris; Aparna Baxi; Akgul Akpinarli; Amy Fulton; Koji Tamada; Scott E Strome; Paul Andrew Antony
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

Review 9.  Induced and natural regulatory T cells in human cancer.

Authors:  Theresa L Whiteside; Patrick Schuler; Bastian Schilling
Journal:  Expert Opin Biol Ther       Date:  2012-07-31       Impact factor: 4.388

10.  Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer.

Authors:  Eleonora Timperi; Ilenia Pacella; Valeria Schinzari; Chiara Focaccetti; Luca Sacco; Francesco Farelli; Roberto Caronna; Gabriella Del Bene; Flavia Longo; Antonio Ciardi; Sergio Morelli; Anna Rita Vestri; Piero Chirletti; Vincenzo Barnaba; Silvia Piconese
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.